Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting
Basile, K.; Rockett, R. J.; McPhie, K.; Fennell, M.; Johnson-Mackinnon, J.; Agius, J.; Fong, W.; Rahman, H.; Ko, D.; Donavan, L.; Hueston, L.; Lam, C.; Arnott, A.; Chen, S.; Maddocks, S.; O'Sullivan, M.; Dwyer, D. E.; Sintchenko, V.; Kok, J.
Show abstract
In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired 15 mutations in the receptor binding domain of the spike protein, raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three and six months post-two doses of Pfizer-BioNTech BNT162b2 has a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres are boosted. Despite this increase, neutralising antibody titres are reduced four-fold for Omicron compared to lineage A.2.2 SARS-CoV-2.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine 96%
- Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern 96%
- NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge 96%
Similar papers in this journal
- Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera 96%
- Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals 96%
- A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model 96%
Similar papers in this journal
- SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity 95%
- Limited impact of Delta variant’s mutations in the effectiveness of neutralization conferred by natural infection or COVID-19 vaccines in a Latino population 95%
- SARS-CoV-2 variants from long-term, persistently infected immunocompromised patients have altered syncytia formation, temperature-dependent replication, and serum neutralizing antibody escape 95%
Similar papers in this journal
- Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine 97%
- SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity 95%
- SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali 95%
Similar papers in this journal
- Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2 95%
- Replication Kinetics, Pathogenicity and Virus-induced Cellular Responses of Cattle-origin Influenza A(H5N1) Isolates from Texas, United States 94%
- Risk assessment of 2024 cattle H5N1 using age-stratified serosurveillance data 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.